Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors - Diagnostic accuracy: NF-pNET and low tumor burden

Digestive Surgery

Volumn 31, Issue 6, 2014, Pages 407-414

  Jilesen, Anneke P J ^a   Busch, Olivier R C ^a   Van Gulik, Thomas M ^a   Gouma, Dirk J ^a   Nieveen Van Dijkum, Els J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chromogranin A; Diagnosis; Follow up; Non functioning pancreatic neuroendocrine tumors

Indexed keywords

CHROMOGRANIN A; TUMOR MARKER;

ADULT; AGED; BLOOD; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; SECONDARY; TUMOR VOLUME;

ADULT; AGED; CHROMOGRANIN A; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84923577472     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000370007     Document Type: Article

References (46)

1. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
2. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134.
3. Lukinius A, Stridsberg M, Wilander E: Cellular expression and specific intragranular localization of chromogranin A, chromogranin B, and synaptophysin during ontogeny of pancreatic islet cells: an ultrastructural study. Pancreas 2003; 27: 38-46.
4. Rindi G, Villanacci V, Ubiali A: Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 2000; 62(suppl 1):19-26.
5. Oberg K: Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18(suppl 1):S17-S25.
6. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al: NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735-752.
7. Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, Kosmidis C, Moulakakis A, Mallas E: Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 2008; 8: 510-519.
8. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443.
9. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60: 644-652.
10. Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, Méndez G, Bestani MC, Parma P, Giacomi N, Marmissolle F: Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Acta Gastroenterol Latinoam 2009; 39: 184-189.
11. Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, et al: Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 867-871.
12. Sidhu R, McAlindon ME, Leeds JS, Skilling J, Sanders DS: The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009; 18: 23-26.
13. Sanduleanu S, De Bruïne A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, et al: Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-811.
14. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
15. Hsiao RJ, Mezger MS, O'Connor DT: Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37: 955-964.
16. Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, et al: Limitations of Chromogranin A in clinical practice. Biomarkers 2012; 17: 186-191.
17. Khan MO, Ather MH: Chromogranin A-serum marker for prostate cancer. J Pak Med Assoc 2011; 61: 108-111.
18. Nobili E, Pezzilli R, Santini D, Campidelli C, Calculli L, Casadei R, et al: Autoimmune pancreatitis associated with high levels of chromogranin a, serotonin and 5-hydroxyindoleacetic acid. Case Rep Gastroenterol 2008; 2: 11-17.
19. Levey AS, Coresh J: Chronic kidney disease. Lancet 2012; 379: 165-180.
20. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
21. Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of the Digestive System, ed 4. IARC WHO Classification of Tumours, 2010, vol 3, p 417 .
22. Popovici T, Moreira B, Schlageter MH, Bories PN: Automated two-site immunofluorescent assay for the measurement of serum chromogranin A. Clin Biochem 2014; 47: 87-91.
23. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-2628.
24. Ferrari L, Seregni E, Lucignani G, Bajetta E, Martinetti A, Aliberti G, Pallotti F, Procopio G, Della Torre S, Luksch R, Bombardier E: Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers 2004; 19: 295-304.
25. Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, et al: Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 2012; 4: 141-155.
26. Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G: Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1992; 144: 49-59.
27. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P: Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 1967-1973.
28. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12(suppl 2):S69-S72.
29. Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, et al: Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 2012; 95: 344-350.
30. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R, Gullo L: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13: 55-58.
31. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. Endocr Relat Cancer 2007; 14: 473-482.
32. de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, et al: Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab 2013; 98: 4143-4151.
33. Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, et al: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102-1107.
34. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-2628.
35. Stridsberg M, Eriksson B, Oberg K, Janson ET: A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177: 337-341.
36. Paik WH, Ryu JK, Song BJ, Kim J, Park JK, Kim YT, Yoon YB: Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. J Korean Med Sci 2013; 28: 750-754.
37. Eriksson B, Arnberg H, et al: Chromogranins-new sensitive markers for neuroendocrine tumors. Acta Oncol 1989; 28: 325-329.
38. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, et al: Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 2012; 152: 965-974.
39. Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, et al: Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011; 150: 75-82.
40. Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, et al: Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with nonfunctioning pancreatic endocrine tumours. Pancreatology 2008; 8: 510-519.
41. Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B, Jensen RT: Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 2003; 98: 249-261.
42. Oberg K: Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med 1998; 70: 501-508.
43. Böttcher J, Hansch A, Pfeil A, Schmidt P, Malich A, Schneeweiss A, et al: Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. Eur J Radiol 2013; 82: 1860-1869.
44. Metser U, Jones C, Jacks LM, Bernardini MQ, Ferguson S: Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography: correlation with surgery and surgical outcome. Int J Gynecol Cancer 2011; 21: 1391-1398.
45. Yang Z, Tang LH, Klimstra DS: Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011; 35: 853-860.
46. Cimitan M, et al: Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003; 14: 1135-1141.